Rare Disease CROs in Netherlands

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Netherlands-based bioanalytical centre of excellence providing large-molecule bioanalysis, immunogenicity, and cell-based assay services for biologics and biosimilar programmes.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.